Condition: Breast Cancer · Gastric Cancer · Esophageal Cancer · Sponsor: Jazz Pharmaceuticals
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
This description comes directly from the study's public registry record.
Clinical Trial Disclosure & Transparency · 215-832-3750 · ClinicalTrialDisclosure@JazzPharma.com
Always discuss trial participation with your own doctor first.
| Arizona Oncology Associates, PC - NAHOA | Prescott, Arizona, United States | Withdrawn |
| Rocky Mountain Cancer Center | Littleton, Colorado, United States | Recruiting |
| Florida Cancer Specialists - South | Fort Myers, Florida, United States | Withdrawn |
| Florida Cancer Specialists - Lake Nona | Orlando, Florida, United States | Active Not Recruiting |
| Florida Cancer Specialists - North | St. Petersburg, Florida, United States | Withdrawn |
| Florida Cancer Specialists - East | West Palm Beach, Florida, United States | Withdrawn |
| Affiliated Oncologists | Chicago Ridge, Illinois, United States | Withdrawn |
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan, United States | Withdrawn |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Alliance Cancer Specialists | Horsham, Pennsylvania, United States | Withdrawn |
| Tennessee Cancer Specialists | Knoxville, Tennessee, United States | Withdrawn |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06695845